All cases of IBD received treatment in the form of 5- aminosalicylic acid (5-ASA), while 54.4% used oral or systemic glucocorticosteroids plus azathioprine,29.1% of cases required biological treatment as anti TNF (Infliximab, Adalimumab) or anti-interleukin IL-12 and IL-23 antibody (Ustekinumab). This evidence concerns the gene TNF and irritable bowel syndrome.